Masafumi Miyata

Prof. Dr. Masafumi Miyata

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2016 in Journal of Neonatal-Perinatal Medicine
Verified
Journal Article
Closed access
PDF file
MMMasafumi Miyata
Masafumi Miyata
KTK. Toyoshima
K. Toyoshima
HYH. Yoda
H. Yoda
MMM. Murase
M. Murase
HKH. Kawato
H. Kawato
MKM. Kobayashi
M. Kobayashi
National surveys were conducted in Japan to assess the current practices for circulatory management of extremely-low-birth-weight infants (ELBWIs) in acute phases. Approximately 80 and 100 institutions were surveyed in 2006 and 2011, respectively. Echocardiography was identified as an important diagnostic tool at 95% of the surveyed institutions. Furthermore, 74% of the institutions survey in 2011 used vasodilator agents. In 2011, the mean velocity of circumferential fiber shortening (mVcfc) and left ventricular end-systolic wall stress (ESWS) were used by 60% of the surveyed institutions to evaluate the relationship between afterload of the left ventricle and left ventricular contractility. Overall, the data collected from these national surveys clarified the current practices for circulatory management of ELBWIs in Japan, particularly the use of echocardiography and cardiovascular agents, including catecholamines and vasodilators.

1 June 2018 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
YHYuki Higashimoto
Yuki Higashimoto
MIMasaru Ihira
Masaru Ihira
YMYu Miyazaki
Yu Miyazaki
AKAyumi Kuboshiki
Ayumi Kuboshiki
SYSayaka Yoshinaga
Sayaka Yoshinaga
TYTetsushi Yoshikawa
Tetsushi Yoshikawa
RotaTeq (RV5) is a widely used live attenuated pentavalent rotavirus (RV) vaccine. Although fecal shedding of RV vaccine strains persists for long time periods, it is unclear how each vaccine strain replicates in intestinal tissue and is excreted in stool. To examine this issue, we established RV5 genotype-specific real-time reverse transcription-PCR (RT-PCR) assays. Five real-time RT-PCR assays were designed for the VP7 gene in genotypes G1, G2, G3, G4, and G6. All assays exhibited excellent linearity, and the detection limit was 1 infectious unit (IU)/reaction for G2, G4, and G6 and 10 IUs/reaction for G1 and G3. No cross-reactivity was observed among G genotypes. The inter- and intra-assay coefficients of variation were less than 3%. The assays were used to examine 129 stool samples collected from eight infants who received RV5. In cases 1 and 2, who received three rounds of vaccination, RV shedding decreased gradually with the number of vaccinations. G1 and G6 shedding appeared to be predominant in comparison to shedding of the other genotypes. Patterns of fecal shedding of the five genotypes of vaccine viruses differed between the eight vaccine recipients. RV5 genotype-specific real-time RT-PCR assays will be useful to study the molecular biology of RV5 replication in infants and experimental animals.

27 April 2026 in Journal of Perinatology
Verified
Journal Article
Open access
Katsumi MizunoKatsumi Mizuno
Katsumi Mizuno
TMTokuo Miyazawa
Tokuo Miyazawa
UKUtako Kondo
Utako Kondo
TNToshiya Nishikubo
Toshiya Nishikubo
YYYutaka Yamamoto
Yutaka Yamamoto
MMMasafumi Miyata
Masafumi Miyata
To determine safety and efficacy of exclusive human milk diet (EHMD) for very low birth weight (VLBW, <1500 g) infants. Prospective, controlled, open trial of VLBW infants randomized to EHMD (mother's own milk [MOM]/donor milk [DM] with human milk-based fortifiers) or Standard Diet (MOM/DM with cow milk-based fortifier/formula). Outcomes included superiority of weight gain velocity from birth to 34 weeks gestational age, time to full feeds, and safety. In total, 147 infants received EHMD (n = 77) or Standard Diet (n = 70). The EHMD group had superior mean weight gain velocity versus the Standard Diet (13.44 vs 11.96 g/kg/day, p = 0.006) and earlier mean time to full feeds (20.0 vs 25.9 days, p = 0.03); adverse events were not significantly different (32.5% vs 21.4%, p = 0.13). EHMD is viable for management of VLBW infants, providing improved growth without reduced safety. Japan Registry of Clinical Trials: jRCT2031210384.

1 January 2023 in Pediatrics International
Verified
Journal Article
Open access
CNChiharuko Nakauchi
Chiharuko Nakauchi
MMMasafumi Miyata
Masafumi Miyata
SKShigemitsu Kamino
Shigemitsu Kamino
YFYusuke Funato
Yusuke Funato
MMMasahiko Manabe
Masahiko Manabe
HBHiroko Boda
Hiroko Boda
Background: Few studies have compared the efficacy and complications of dexmedetomidine (DEX) and fentanyl (FEN) in extremely preterm infants.Methods: We conducted a single‐institution, retrospective controlled before and after study of preterm infants before 28 weeks of gestation admitted between April 2010 and December 2018 to compare the complications and efficacy of DEX and FEN for preterm infants. Patients were administered FEN prior to 2015 and DEX after 2015 as the first‐line sedative. A composite outcome of death during hospitalization and developmental quotient (DQ) < 70 at a corrected age of 3 years was compared as the primary outcome. Secondary outcomes including postmenstrual weeks at extubation, days of age when full enteral feeding was achieved and additional sedation by phenobarbital (PB) were compared.Results: Sixty‐six infants were enrolled into the study. The only perinatal factor that differed between the FEN (n = 33) and DEX (n = 33) groups was weeks of gestation. The composite outcome of death and DQ < 70 at a corrected age of 3 years were not significantly different. Postmenstrual weeks at extubation did not significantly differ between groups after adjustment for weeks of gestation and being small for gestational age. On the other hand, full feeding was significantly prolonged by DEX (p = 0.031). Additional sedation was less common in the DEX group (p = 0.044).Conclusion: The composite outcome of death and DQ < 70 at a corrected age of 3 years were not significantly different by DEX or FEN for primary sedation. Prospective randomized controlled trials should examine the long‐term effects on development.

26 October 2015 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
JMJun Miyazaki
Jun Miyazaki
MIMayuko Ito
Mayuko Ito
HNHaruki Nishizawa
Haruki Nishizawa
TKTakema Kato
Takema Kato
YMYukito Minami
Yukito Minami
TFTAKUMA FUJII
TAKUMA FUJII
In the present study, we report on a couple who underwent prenatal genetic diagnosis for autosomal recessive polycystic kidney disease (ARPKD). This healthy couple had previously had a healthy boy but had experienced two consecutive neonatal deaths due to respiratory distress resulting from pulmonary hypoplasia caused by oligohydramnios. The woman consulted our facility after she realized she was pregnant again. We promptly performed a carrier test for the PKHD1 gene by target exome sequencing of samples from the couple. A pathogenic mutation was identified only in the paternal allele (c.9008C>T, p.S3003F). The mutation was confirmed by Sanger sequencing of the DNA from formalin-fixed, paraffin-embedded, kidney tissue of the second neonate patient and was not found in the healthy sibling. We then performed haplotype analyses using microsatellite markers scattered throughout the PKHD1 gene. DNA from the amniocentesis was determined to belong to a carrier, and the couple decided to continue with the pregnancy, obtaining a healthy newborn. Subsequent detailed examination of the exome data suggested higher read depth at exons 45 and 46. Multiplex ligation-dependent probe amplification allowed identification of duplication of these two exons. This case suggests the potential usefulness of target exome sequencing in the prenatal diagnosis of the PKHD1 gene in ARPKD. This is the first report of intragenic duplication in the PKHD1 gene in ARPKD.

1 January 2022 in Pediatrics International
Verified
Journal Article
Closed access
YKYuri Kawai
Yuri Kawai
MHMasahiro Hayakawa
Masahiro Hayakawa
TTTaihei Tanaka
Taihei Tanaka
YYYasumasa Yamada
Yasumasa Yamada
ANAtsushi Nakayama
Atsushi Nakayama
MMMasafumi Miyata
Masafumi Miyata